Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients

American Journal of Nephrology

Volumn 33, Issue 5, 2011, Pages 421-426

  Takeda, Yoko ^a   Komaba, Hirotaka ^a,b   Goto, Shunsuke ^a   Fujii, Hideki ^a   Umezu, Michio ^a   Hasegawa, Hirohito ^c   Fujimori, Akira ^d   Nishioka, Masato ^e   Nishi, Shinichi ^a   Fukagawa, Masafumi ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c Konan Hospital Foundation Rokko Island Hospital   (Japan)

^d Konan Hospital   (Japan)

^e Sumiyoshigawa Clinic   (Japan)

Author keywords

FGF23; Hemodialysis; Iron deficiency anemia; Parathyroid hormone; Saccharated ferric oxide

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; IRON SACCHARATE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY ANEMIA; MALE; MINERAL METABOLISM; MULTICENTER STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

AGED; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HUMANS; INFUSIONS, INTRAVENOUS; INTERVENTION STUDIES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHATES; PROSPECTIVE STUDIES; RENAL DIALYSIS; VITAMIN D;

EID: 79955077596     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000327019     Document Type: Article

References (34)

1. Quarles LD: Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-3828.
2. Saito H, Kusano K, Kinosaki M, et al: Human fibroblast growth factor-23 mutants suppress Na-dependent phosphate cotransport activity and 1α, 25-dihydroxyvitamin D 3 production. J Biol Chem 2003;278:2206-2211. (Pubitemid 36801287)
3. Shimada T, Hasegawa H, Yamazaki Y, et al: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-435. (Pubitemid 38787398)
4. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-4008. (Pubitemid 350224109)
5. Krajisnik T, Bjorklund P, Masell R, et al: Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-131. (Pubitemid 350056006)
6. ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-348.
7. Yamazaki Y, Okazaki R, Shibata M, et al: increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-4960. (Pubitemid 35316332)
8. Jonsson KB, Zahradnik R, Larsson T, et al: Fibroblast growth factor-23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-1663. (Pubitemid 36459471)
9. Shimada T, Mizutani S, Muto T, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-6505. (Pubitemid 32488266)
10. Kurosu H, Ogawa Y, Miyoshi M, et al: Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006;281:6120-6123. (Pubitemid 43847540)
11. Urakawa I, Yamazaki Y, Shimada T, et al: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-774. (Pubitemid 44949607)
12. Komaba H, Fukagawa M: FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010;77:292-298.
13. Gutiérrez OM: Fibroblast growth factor-23 and disordered vitamin D metabolism in chronic kidney disease: updating the 'tradeoff' hypothesis. Clin J Am Soc Nephrol 2010;5:1710-1716.
14. Shigematsu T, Yamashita T, Fukumoto S, et al: Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44:250-256. (Pubitemid 38962552)
15. Gutierrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-2215. (Pubitemid 41716454)
16. Nishi H, Nii-Kono T, Nakanishi S, et al: Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005;101: c94-c99. (Pubitemid 41208897)
17. Nakanishi S, Kazama JJ, Nii-Kono T, et al: Serum fibroblast factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-1178. (Pubitemid 41623344)
18. Kazama JJ, Sato F, Omori K, et al: Pretreatment serum FGF23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005;67:1120-1125. (Pubitemid 41623338)
19. Gutierrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
20. Jean G, Terrat JC, Vanel T, et al: High levels of serum fibroblast growth factor-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009;24:2792-2796.
21. Shimizu Y, Tada Y, Yamauchi M, et al: Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009;45:814-816.
22. Schouten BJ, Hunt PJ, Livesey JH, et al: FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009;94:2332-2337.
23. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 1997;29:319-333. (Pubitemid 27106553)
24. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906.
25. Payne RB, Little AJ, Williams RB, Milner JR: Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973;4:643-646.
26. Okada M, Imamura K, Fuchigami T, et al: Two cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide (in Japanese). Nippon Naika Gakkai Zasshi 1982;71:1566-1572.
27. Okada M, Imamura K, Iida M, et al: Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr 1983;61:99-102. (Pubitemid 13182839)
28. Sato K, Shiraki M: Saccharated ferric oxideinduced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J 1998;45:431-439. (Pubitemid 28477653)
29. Ishii K, Fumoto T, Iwai K, et al: Coordination of PGC-1β and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009;15:259-266.
30. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD: Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003;278:37419-37426. (Pubitemid 37175262)
31. Komaba H, Goto S, Fujii H, et al: Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010;77:232-238.
32. Kumata C, Mizobuchi M, Ogata H, et al: Involvement of a-Klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol 2010;31:230-238.
33. Galitzer H, Ben-Dov IZ, Silver J, et al: Parathyroid cell resistance to fibroblast growth factor-23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010;77:211-218.
34. Canalejo R, Canalejo A, Martinez-Moreno JM, et al: FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010;21:1125-135.